David Wallace is an Executive Editor for Generics Bulletin, a leading publication in the pharmaceutical industry. With a focus on the generics and biosimilars market, David covers a wide range of topics including industry news, regulatory updates, and market trends. His work has been featured in various publications including IDC, Yahoo News UK, Informa, Knowledia, Combating Terrorism Center, and The Union.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
David Wallace's coverage primarily focuses on press releases and private sector announcements related to the healthcare, pharmaceutical, and biotechnology industries. He covers topics such as biosimilars, European industry news, medicines, and pharmaceutical companies' activities.
If you have updates or insights related to new developments in the pharmaceutical or biotechnology sectors, particularly regarding product launches, regulatory approvals or market trends in Europe and the US, your pitch is likely to resonate with David. Additionally, if you represent a company making significant strides in these areas or have exclusive access to industry data that can inform his coverage of private sector announcements within these sectors.
As he has specific themes covered like healthcare & pharmaceuticals along with biotechnology; it’s important for any expert commentary provided aligns closely with these themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: David Wallace
Days after Sandoz received US FDA approval for its Enzeevu aflibercept biosimilar rival to Regeneron's Eylea, the originator has hit the firm with a lawsuit alleging that it failed to follow the “patent dance” set out in the BPCIA biosimilars framework and claiming infringement of multiple patents.
Medicines Patent Pool Says It Is Ready To Play A Part In Global Response
By: David Wallace
Showcasing the sponsors of this year's Global Generics & Biosimilars Awards, we spotlight Aurobindo which is sponsoring the Industry Partner Of The Year award in 2024.
By: David Wallace
Hikma has asked the US Court of Appeals for the Federal Circuit for a full court rehearing of a panel decision that earlier this year reopened a dispute with Amarin over a skinny-label generic version of Vascepa.
Days after Sandoz received US FDA approval for its Enzeevu aflibercept biosimilar, Regeneron sued alleging that Sandoz failed to follow the “patent dance” set out in the BPCIA framework and claiming infringement of multiple patents on its Eylea.
By: David Wallace
Fresenius Kabi has completed the divestment of its Chilean subsidiary Laboratorio Sanderson to Peru's Medifarma, including the transfer of an IV drug facility in Santiago de Chile, as part of streamlining the German group's manufacturing operations.
By: David Wallace
Chanelle Pharma has named a new chief executive officer and set out ambitious plans to expand its workforce, while Enzene Biosciences has appointed a new facility head and Perrigo has created a brand and digital role on its top management team.
By: David Wallace
The final shortlist of entries across all 14 categories of the Global Generics & Biosimilars Awards 2024 has now been revealed, ahead of our prizegiving ceremony in Milan on 9 October.
By: David Wallace
Glenmark Pharmaceuticals has agreed a $25m payout in the US to resolve its alleged liability under the False Claims Act linked to historical price-fixing allegations.
By: David Wallace
Samsung Bioepis and Alexion have brought patent proceedings over Soliris to an end in the US, clearing the way for the Korean firm to launch its Epysqli biosimilar version of eculizumab. However, Amgen is also waiting in the wings with its own rival.
(833) 317-6278 
